English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04620330 /

VS-6766-202

A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: